A meta-analysis encompassing seven cardiovascular outcome trials (CVOTs) with approximately 56,000 patients diagnosed with T2DM found that the use of GLP-1 receptor agonists was associated with a 15% decrease in the incidence of nonfatal stroke [35]. Here, GLP1R is linked to Stroke.